Healthcare
YD Bio Limited Warrants(YDESW)
Live Price
Offline$0.2502
-15.19% today
Window Change
-36.77%
Window
Aug 29, 2025 → Jun 15, 2026
- Market Cap
- $350.00M
- Revenue Growth
- +45.8%
- EPS Growth
- -280100.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 196 bars · Aug 29, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
YD Bio Limited Warrants (YDESW) is a Healthcare stock with a market cap of $350.00M and listed on NASDAQ. The stock last traded around $0.25 and down 36.8% across the available one-year price window (Aug 29, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of -280100.0%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS -280100.0%, free cash flow -8386.3% with operating margin 0.0% and ROIC 13.6%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines YDESW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+45.8% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +45.8% and EPS is at -280100.0%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YDESW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YDESW Max Drawdown
-89.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for YDESW and SPY.
Company Overview
YD Bio Limited Warrants
NASDAQ Global Select
YD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.
- Leadership
- Ethan Shen
- IPO Date
- Aug 29, 2025
- Employees
- 4
- Street Address
- No. 3, Xingnan St.
- Mailing
- Taipei, 115001
- Region
- Taipei, TW
- Reporting Currency
- USD
- Investor Line
- +852 3590 6121
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- +45.8%
- EPS
- -280100.0%
- Free Cash Flow
- -8386.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 68.2%
- ROIC
- 13.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.